Strs Ohio increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 32.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,000 shares of the biopharmaceutical company’s stock after buying an additional 3,900 shares during the period. Strs Ohio’s holdings in Amicus Therapeutics were worth $249,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Exane Derivatives purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $137,000. Palisade Capital Management LLC NJ purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $211,000. TCW Group Inc. purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $245,000. Rockefeller Capital Management L.P. purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $288,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $318,000.
Several equities analysts have recently weighed in on FOLD shares. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. BidaskClub downgraded shares of Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 18th. Finally, Chardan Capital downgraded shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a research note on Friday, August 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average target price of $19.33.
In other news, major shareholder Perceptive Advisors Llc bought 20,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, September 24th. The stock was bought at an average cost of $12.45 per share, with a total value of $249,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive bought 500,000 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, September 12th. The stock was purchased at an average cost of $12.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 620,000 shares of company stock valued at $7,505,000 over the last three months. 2.90% of the stock is currently owned by insiders.
Amicus Therapeutics stock traded up $0.25 during mid-day trading on Friday, reaching $13.44. 4,279,719 shares of the company traded hands, compared to its average volume of 2,630,857. The company has a market cap of $2.29 billion, a P/E ratio of -4.60 and a beta of 1.33. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30. Amicus Therapeutics, Inc. has a 52-week low of $11.57 and a 52-week high of $17.62.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The business had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million. Analysts predict that Amicus Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.